Inhibition of nuclear factor-κB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line

This publication has 35 references indexed in Scilit:

• Nuclear Factor-κB Activation: A Question of Life or Death
  BMB Reports, 2002
• Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
  Journal of Clinical Investigation, 2001
• Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide
  Oncogene, 2000
• Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats
  Kidney International, 1999
• Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
  Journal of Clinical Investigation, 1997
• Combination paclitaxel (TaxolR)-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer
  International Journal of Gynecologic Cancer, 1997
• Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death
  Cell, 1996
• THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
  Annual Review of Immunology, 1996
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Function and Activation of NF-kappaB in the Immune System
  Annual Review of Immunology, 1994